Resected Pancreatic Cancer With N2 Node Involvement Is Refractory to Gemcitabine-Based Adjuvant Chemotherapy
Liu C, Cheng H, Jin K, Fan Z, Gong Y, Qian Y, Deng S, Huang Q, Ni Q, Yu X, Luo G. Resected Pancreatic Cancer With N2 Node Involvement Is Refractory to Gemcitabine-Based Adjuvant Chemotherapy. Cancer Control 2020, 27: 1073274820915947. PMID: 32268796, PMCID: PMC7153189, DOI: 10.1177/1073274820915947.Peer-Reviewed Original ResearchMeSH KeywordsChemotherapy, AdjuvantDeoxycytidineDrug Resistance, NeoplasmFemaleGemcitabineHumansLymph NodesLymphatic MetastasisMaleMiddle AgedPancreatic NeoplasmsConceptsGemcitabine-based adjuvant chemotherapyResectable pancreatic cancerPancreatic cancerAdjuvant chemotherapyN2 node involvementNode involvementCurative resection of pancreatic adenocarcinomaResection of pancreatic adenocarcinomaGemcitabine-based regimenGemcitabine-based treatmentNode-positive subgroupEfficacy of gemcitabineGemcitabine-based chemotherapyN2 tumorsAdjuvant regimenNodal involvementNodal statusNode-negativeCurative resectionPancreatic adenocarcinomaSubgroup patientsLymphatic metastasisChemotherapyPatientsCancer